Download Cancer Pharmacogenomics and Targeted Therapies

Cancer Pharmacogenomics and Targeted Therapies
15-17 September 2013
Wellcome Trust Conference Centre, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK
The development of new cancer therapies is increasingly guided by our understanding of the
molecular basis of cancer. As worldwide efforts are beginning to provide a comprehensive description
of the genomic, transcriptomic and epigenomic changes that occur in cancer, the field of cancer
pharmacogenomics will be at the forefront of a new generation of rationally designed cancer therapies
incorporating molecular biomarkers. These hold the promise of improved clinical responses by
enabling the stratification of patients most likely to benefit from a specific treatment.
This conference is aimed at scientists and clinician-scientists in academia or industry and will seek to
address many of the key challenges in the design, development and clinical implementation of
targeted cancer therapies.
Scientific topics will include:
• Cancer Genomics
• Drugging the Cancer Genome
• Experimental and pre-clinical therapeutic models
• Combating drug resistance
• Molecular biomarkers in the clinic
Scientific Organisers
Rene Bernards The Netherlands Cancer Institute
Mathew Garnett Wellcome Trust Sanger Institute, UK
Ultan McDermott Wellcome Trust Sanger Institute, UK
Mike Stratton Wellcome Trust Sanger Institute, UK
Dave Tuveson Cold Spring Harbor Laboratory, USA
Confirmed speakers include:
Bissan Al-Lazikani Institute for Cancer Research, London, UK
Alberto Bardelli Institute for Cancer Research and Treatment at Candiolo, Italy
Lynda Chin MD Anderson Cancer Centre, USA
Johann de Bono Institute for Cancer Research, London, UK
Julian Downward Cancer Research UK London Research Institute
Mikala Egeblad Cold Spring Harbour Laboratories, USA
Jeff Engelman Massachusetts General Hospital Cancer Center, USA
Manel Esteller Cancer Epigenetics and Biology Program, Spain
Keith Flaherty Massachusetts General Hospital, USA
Levi Garraway Dana Faber Cancer Institute, USA
Stefan Pfister German Cancer Research Center
David Rees Astex Pharmaceuticals, USA
David B. Solit Memorial Sloan-Kettering Cancer Center, USA
Robert Vries Hubrecht Institute, The Netherlands
Lodewyk Wessels TheNetherlands Cancer Institute
Paul Workman Institute for Cancer Research, London, UK
Registration & Abstract Deadline: 28 June 2013
Full details can be found at https://registration.hinxton.wellcome.ac.uk/display_info.asp?id=348